Background: Recent reports have indicated that loss-of-function mutations in the immunoglobulin superfamily member 1 gene (IGSF1, OMIM 300888) cause congenital central hypothyroidism with macroorchidism. Methods: We conducted a next-generation sequencing-based comprehensive mutation screening for pituitary hormone deficiencies to elucidate molecular mechanisms other than anatomical abnormalities of the pituitary that might be responsible for multiple anterior hormone deficiency in a male patient who originally visited our institute complaining of short stature. He was born large for gestational age (4,370 g, +3.0 SD) after an obstructed labour. Endocrinological evaluation revealed growth hormone and thyroid-stimulating hormone deficiency. Magnetic resonance imaging showed a discontinuity of the pituitary stalk with an ectopic posterior lobe and a hypoplastic anterior lobe, likely explaining multiple anterior pituitary hormone deficiency. Re sult: We identified a novel hemizygous IGSF1 mutation (c.1137_1138delCA, p.Asn380Glnfs*6) in the patient. In reviewing the literature, we noticed that all reported Japanese male IGSF1 mutation carriers were born larger than mean standards for gestational age (mean birth weight SD score of +2.0, 95% confidence interval 1.0-3.0). Conclusion: This case suggests that more attention should be paid to intrauterine growth and birth history when patients are suspected of having an IGSF1 mutation.

Keywords:
Invisible stalk, Large for gestational age, Central hypothyroidism, IGSF1, Growth hormone deficiency
1.
Sun Y, Bak B, Schoenmakers N, van Trotsenburg AS, Oostdijk W, Voshol P, Cambridge E, White JK, le Tissier P, Gharavy SNM, Martinez-Barbera JP, Stokvis-Brantsma WH, Vulsma T, Kempers MJ, Persani L, Campi I, Bonomi M, Paolo Beck-Peccoz P, Zhu H, Davis TME, Hokken-Koelega ACS, Del Blanco DG, Rangasami JJ, Ruivenkamp CAL, Laros JFJ, Kriek M, Kant SG, Bosch CAJ, Biermasz NR, Appelman-Dijkstra NM, Corssmit EP, Hovens GCJ, Pereira AM, den Dunnen JT, Wade MG, Breuning MH, Hennekam RC, Chatterjee K, Dattani MT, Wit JM, Bernard DJ: Loss-of-function mutations in IGSF1 cause an X-linked syndrome of central hypothyroidism and testicular enlargement. Nat Genet 2012;44:1375-1381.
2.
Joustra SD, Schoenmakers L, Persani L, Campi M, Bonomi G, Radetti G, Beck-Peccoz P, Zhu H, Davis TME, Sun Y, Corssmit EP, Appelman-Dijkstra NM, Heinen CA, Pereira AM, Varewijck AJ, Janssen JAMJL, Endert E, Hennekam RC, Lombardi MP, Mannens MMAM, Bak B, Bernard DJ, Breuning MH, Chatterjee K, Dattani MT, Oostdijk W, Biermasz NR, Wit JM, van Trotsenburg ASP: The IGSF1 deficiency syndrome: characteristics of male and female patients. J Clin Endocrinol Metab 2013;98:4942-4952.
3.
Tajima T, Nakamura A, Ishizu K: A novel mutation of IGSF1 in a Japanese patient of congenital central hypothyroidism without macroorchidism. Endocr J 2013;60:245-249.
4.
Nakamura A, Bak B, Silander TL, Lam J, Hotsubo T, Yorifuji T, Ishizu K, Bernard DJ, Tajima T: Three novel IGSF1 mutations in four Japanese patients with X-linked congenital central hypothyroidism. J Clin Endocrinol Metab 2013;98:E1682-E1691.
5.
Isojima T, Shimatsu A, Yokoya S, Chihara K, Tanaka T, Hizuka N, Teramoto A, Tatsumi K, Tachibana K, Katsumata N, Horikawa R: Standardized centile curves and reference intervals of serum insulin-like growth factor-I (IGF-I) levels in a normal Japanese population using the LMS method. Endocr J 2012;59:771-780.
6.
Takagi M, Narumi S, Asakura Y, Muroya K, Hasegawa Y, Adachi M, Hasegawa T: A novel mutation in SOX2 causes hypogonadotropic hypogonadism with mild ocular malformation. Horm Res Paediatr 2014;81:133-138.
7.
Mazzarella R, Pengue G, Jones J, Jones C, Schlessinger D: Cloning and expression of an immunoglobulin superfamily gene (IGSF1) in Xq25. Genomics 1998;48:157-162.
8.
Frattini A, Faranda S, Redolfi E, Allavena P, Vezzoni P: Identification and genomic organization of a gene coding for a new member of the cell adhesion molecule family mapping to Xq25. Gene 1998;214:1-6.
9.
Robakis T, Bak B, Lin SH, Bernard DJ, Scheiffele P: An internal signal sequence directs intramembrane proteolysis of a cellular immunoglobulin domain protein. J Biol Chem 2008;283:36369-36376.
10.
Tanaka T, Tachibana K, Shimatsu A, Katsumata N, Tsushima T, Hizuka N, Fujieda K, Yokoya S, Irie M: A nationwide attempt to standardize growth hormone assays. Horm Res 2005;64(suppl 2):6-11.
11.
Asakura Y, Muroya K, Adachi M, Narumi S, Hasegawa T: Standard values of TSH reaction to TRH test: changes in free T4 and free T3. Horumon To Rinnsho 2010;58:1057-1062.
12.
Kouka K, Tanaka T, Miyagawa N, Takeda H: Evaluation of analytical performance and reference range of new prolactin reagent-ECLusys PRL III using automatic electro-chemiluminescence assay analyser ‘Modular Analytics <E>'. Jpn J Med Pharm Sci 2006;56:577-586.
13.
Ito J, Tanaka T, Horikawa R, Okada Y, Morita S, Kokaji M, Tanae Y, Hibi I: Clinical study on the time-resolved fluoroimmunoassay of serum luteinizing hormone and follicle stimulating hormone in children: the change of serum gonadotropins in LHRH test and night time secretion during puberty. J Jpn Pediatr Soc 1993;97:1797-1804.
14.
Itabashi K, Fujimura M, Kusuda S, et al: New normal birth-weight for Japanese infant according to gestational age at delivery (in Japanese). J Jpn Pediatr Soc 2010;114:1271-1293.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.